clinical trial · NCT05041309
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Kite, A Gilead Company·—·enrolling by invitation·n = 1,000
Solid and Hematological MalignanciesAxicabtagene CiloleucelBrexucabtagene AutoleucelAnitocabtagene autleucelKITE-753KITE-197KITE-363
brief summary
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, and anitocabtagene autoleucel in participants of Kite-sponsored interventional studies.
started
Dec 15, 2021
primary completion
Dec 1, 2040
completion
Dec 1, 2040
last updated
Feb 25, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol